AI Summary
✦ ClarthaPrice Forecast
Probabilistic Range
Probabilistic lognormal cone using 1Y realized volatility and analyst-target drift when available.
Revenue Forecast
₹ CrEPS Forecast
₹ / shareMulti-factor synthesis of 5 key dimensions
From 4 analysts
Fundamentals
Fundamentals institutional score is 100 using growth durability 100.0.
Valuation
Valuation institutional score is 2 using relative multiple z-scores where peer dispersion is available.
Analyst Consensus
Analyst View institutional score is 76 using mean target upside 4.9%; dispersion penalty 4.1; recommendation breadth from available consensus.
Technical Structure
Technicals institutional score is 0 using EMA-20 continuation within 5% tolerance; VCP range/volume contraction proxy.
Market Sentiment
Recent news flow is balanced or not decisive enough to tilt the tape. Based on 2 recent ticker-linked news items.
Signal Summary
Market intelligence remains Mixed. fundamentals and analyst consensus provide support, while valuation and technical structure remain considerations.
Composite weights: Fundamentals 25%, Valuation 20%, Analyst Consensus 20%, Technical Structure 20%, Market Sentiment 15%.
Key Data Points
Important Note: This is market intelligence, not investment advice. Always conduct your own research and consider your financial goals and risk tolerance.
Valuation Metrics
Trading 80.5% above historical median. Valuation is rising — currently in the strongly overvalued zone (z-score: +2.41). Confidence: 61%.
Live forward EPS implies next-12-month EPS of ₹490.83. Applying the stock's normalized valuation corridor produces a fair range of ₹8,992.01 to ₹19,024.57, with base value near ₹16,089.41 (-28.5% vs current price).
Live forward estimate anchored to the company's historical valuation corridor.
Forward EPS
₹490.83
Forward P/E
45.9x
Base Fair Value
₹16,089.41
Fair Range
₹8,992.01 - ₹19,024.57
Upside To Base
-28.5%
Estimate Source
Live forward EPS
Growth Estimate
+962.8%
5Y Average
20.68
Current
59.17
Overvalued
38.76
Undervalued
18.32
5Y Average
72.03
Current
544.86
Overvalued
93.44
Undervalued
35.39
5Y Average
16.66
Current
47.68
Overvalued
28.03
Undervalued
3.50
Peers & Comparison
Sector: Health Care · Theme: Pharmaceuticals
| Company | Rev. Growth | Margin | P/E | vs Avg | 52W Perf. |
|---|---|---|---|---|---|
CIPLA LTD CIPLAPharmaceuticals | +3.5% | 12.0% | 35.0x Fair | +3% vs avg | -6.5% |
AJANTA PHARMA LIMITED AJANTPHARMPharmaceuticals | +24.8% | 19.6% | 39.9x Premium | +17% vs avg | +31.8% |
LUPIN LIMITED LUPINPharmaceuticals | +32.0% | 18.5% | 18.6x Undervalued | -45% vs avg | +16.3% |
MANKIND PHARMA LIMITED MANKINDPharmaceuticals | +12.9% | 13.9% | 48.6x Premium | +43% vs avg | -1.6% |
ABBOTT INDIA LIMITED ABBOTINDIAPharmaceuticals | +6.5% | 22.4% | 37.8x Fair | +11% vs avg | -15.4% |
ZYDUS LIFESCIENCES LTD ZYDUSLIFEPharmaceuticals | +22.0% | 15.8% | 25.7x Undervalued | -24% vs avg | +21.9% |
GLENMARK PHARMACEUTICALS GLENMARKPharmaceuticals | +23.1% | 10.1% | 36.4x Fair | +7% vs avg | +12.0% |
DR. REDDY S LABORATORIES DRREDDYPharmaceuticals | -5.6% | 10.0% | 30.4x Fair | -11% vs avg | -4.8% |
NEULAND LAB LTD. trades at a premium (59.9x vs peer avg 34.0x), implying higher growth or quality expectations from the Pharmaceuticals cohort. Peers include CIPLA LTD, AJANTA PHARMA LIMITED, LUPIN LIMITED — selected based on business model, industry classification, market cap similarity, and business theme alignment.
Financials
Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.
Latest revenue
₹642 CrJun 2026Latest net profit
₹147 CrJun 2026Latest EPS
₹114.86Jun 2026Net margin
35.0%Jun 2026Performance
Bars show revenue and net profit. The line shows net margin.
- Revenue
- Net income
- Net margin %
Earnings
Revenue is shown in crores. EPS is rupees per share.
- Revenue
- EPS
Revenue to profit conversion
Bridge from operating numbers to profit for the latest reported period.
Latest reported period: Jun 2026
Debt level and coverage
Debt, cash and free cash flow compared on the same crore scale.
- Debt
- Free cash flow
- Cash & equivalents
Results
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 363 | 418 | 393 | 385 | 440 | 311 | 398 | 328 | 293 | 514 | 440 | 776 | 642 |
| Expenses + | 266 | 280 | 272 | 278 | 316 | 250 | 312 | 278 | 258 | 359 | 363 | 469 | 419 |
| Operating Profit | 97 | 137 | 121 | 107 | 124 | 61 | 86 | 51 | 34 | 155 | 77 | 307 | 223 |
| OPM % | 27% | 33% | 31% | 28% | 28% | 20% | 22% | 15% | 12% | 30% | 18% | 40% | 35% |
| Other Income + | 2 | 3 | 2 | 5 | 25 | 4 | 60 | 7 | 8 | 2 | 8 | 12 | 8 |
| Interest | 2 | 4 | 4 | 4 | 3 | 1 | 2 | 2 | 5 | 5 | 7 | 7 | 7 |
| Depreciation | 14 | 15 | 15 | 16 | 16 | 16 | 16 | 17 | 20 | 23 | 24 | 25 | 27 |
| Profit before tax | 84 | 121 | 104 | 92 | 130 | 49 | 128 | 39 | 17 | 129 | 54 | 287 | 198 |
| Tax % | 25% | 27% | 22% | 27% | 25% | 34% | 20% | 29% | 21% | 25% | 26% | 26% | 25% |
| Net Profit + | 62 | 89 | 81 | 68 | 98 | 32 | 101 | 28 | 14 | 96 | 40 | 213 | 147 |
| EPS in Rs | 48.50 | 69.42 | 62.90 | 52.70 | 76.65 | 24.91 | 79.03 | 21.61 | 10.69 | 75.18 | 31.50 | 165.64 | 114.86 |
| Raw PDF |
All values in ₹ Crores unless otherwise stated. Source: Screener Master (Standalone).
Events Timeline
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation